# Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice

> **NCT02655159** · — · TERMINATED · sponsor: **Celgene Corporation** · enrollment: 46 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02655159
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Given the infeasibility to achieve the study population together with the loss of originality in the scientific rationale, it was considered to cancel the study
- **Last updated:** 2016-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02655159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02655159, "Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02655159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*